Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA

Intervention/treatment:
SELINEXOR
Medical condition:
ENDOMETRIAL CANCER
Protocol code:
XPORT-EC-042
Control number:
268207
Status:
Active, not recruiting
Approved:
October 28, 2022
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT05611931
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Karyopharm Medical Information
Role
CONTACT
Phone:
(888) 209-9326
Sponsor
KARYOPHARM THERAPEUTICS, INC.

Locations

Alberta

Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
NOT_YET_RECRUITING
Name
Jennifer Rauw
Role
CONTACT
Name
Jennifer Rauw
Role
PRINCIPAL_INVESTIGATOR
Tom Baker Cancer Centre
Calgary, Alberta, T3H2G5
RECRUITING
Name
Prafull Ghatage
Role
CONTACT
Name
Prafull Ghatage
Role
PRINCIPAL_INVESTIGATOR

Nova Scotia

Nova Scotia Health / QEII Health Sciences Centre / Atlantic Clinical Cancer Research Unit
Halifax, Nova Scotia, B3H 2Y9
RECRUITING
Name
Alison Avery
Role
CONTACT
Phone:
902-473-7351
Name
Katharina Kieser
Role
PRINCIPAL_INVESTIGATOR

Ontario

Princess Margaret
Toronto, Ontario, M5G 2M9
RECRUITING
Name
Lila Shapiro
Role
CONTACT
Phone:
416-946-4501
Name
Amit Oza
Role
PRINCIPAL_INVESTIGATOR
Sunnybrook Research Institute
Toronto, Ontario, M9L 2H9
RECRUITING
Name
Nithla Mohanathas
Role
CONTACT
Phone:
416-480-5000
Name
Al Covens
Role
PRINCIPAL_INVESTIGATOR

Quebec

Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, H2X 0C1
RECRUITING
Name
Bonny Choy
Role
CONTACT
Phone:
514-890-8000 x24672
Name
Vanessa Samouëlian
Role
PRINCIPAL_INVESTIGATOR
Hospital Maisonneuve-Rosemont
Montreal, Quebec, M9L 2H9
RECRUITING
Name
Suzanne Fortin
Role
CONTACT
Name
Suzanne Fortin
Role
PRINCIPAL_INVESTIGATOR
McGill University Health Centre (MUHC)
Montreal, Quebec, H4A3J1
RECRUITING
Name
Nathalie Nguyen-Phuong-Nam
Role
CONTACT
Name
Lucy Gilbert
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?

Contacts and resources